Department of Cardiovascular Surgery, The Second Hospital of Shandong University, Jinan 250000, China.
Biomed Res Int. 2021 Dec 3;2021:5431985. doi: 10.1155/2021/5431985. eCollection 2021.
This study aimed at observing the expression of lncRNA-ANRIL (ANRIL) before and after treatment and its predictive value for short-term survival in patients with coronary heart disease (CHD). Altogether, 112 patients with CHD admitted to the hospital were enrolled as a study group (SG), which was divided into a pretreatment study group (preSG) and a posttreatment study group (postSG). Further 72 healthy people undergoing physical examinations during the same period were enrolled as a control group (CG). Peripheral blood was collected from the subjects in the three groups, to detect the expression level of serum ANRIL using quantitative reverse transcription PCR (qRT-PCR). A receiver operating characteristic (ROC) curve was plotted to evaluate the diagnostic value of ANRIL for CHD. Kaplan-Meier survival curves were plotted to analyze 3-year survival rates in high- and low-ANRIL expression groups. Cox regression was conducted to analyze independent risk factors affecting the patients. The expression level of serum ANRIL in preSG was significantly lower than those in CG and postSG ( < 0.05). According to the ROC curve, the area under the curve (AUC) of serum ANRIL for diagnosing CHD in CG was 0.894 and the optimal cutoff value was 0.639, with the sensitivity of 86.61% and the specificity of 93.67%. According to the survival curves, the 3-year overall survival rate in the high-ANRIL expression group was significantly lower than that in the low-expression group ( < 0.05). History of smoking, high total cholesterol (TC), high triglyceride (TG), high homocysteine (Hcy), and ANRIL expression were independent prognostic factors affecting the overall survival time of the patients ( < 0.05). ANRIL is poorly expressed in the peripheral blood of patients with CHD. Its detection has good sensitivity and specificity for diagnosing the disease, and its expression may be related to the poor prognosis of the patients.
本研究旨在观察长链非编码 RNA-ANRIL（ANRIL）在冠心病（CHD）患者治疗前后的表达及其对短期生存的预测价值。共纳入 112 例住院 CHD 患者为研究组（SG），分为治疗前研究组（preSG）和治疗后研究组（postSG）。同期纳入 72 名健康体检者为对照组（CG）。采集三组受试者外周血，采用实时荧光定量逆转录聚合酶链反应（qRT-PCR）检测血清 ANRIL 表达水平。绘制受试者工作特征（ROC）曲线评估 ANRIL 对 CHD 的诊断价值。绘制 Kaplan-Meier 生存曲线分析高、低 ANRIL 表达组 3 年生存率。采用 Cox 回归分析影响患者的独立危险因素。preSG 血清 ANRIL 表达水平明显低于 CG 和 postSG（ < 0.05）。ROC 曲线显示，CG 中血清 ANRIL 诊断 CHD 的曲线下面积（AUC）为 0.894，最佳截断值为 0.639，灵敏度为 86.61%，特异性为 93.67%。根据生存曲线，高表达组患者 3 年总生存率明显低于低表达组（ < 0.05）。吸烟史、总胆固醇（TC）、甘油三酯（TG）、高同型半胱氨酸（Hcy）及 ANRIL 表达是影响患者总生存时间的独立预后因素（ < 0.05）。CHD 患者外周血中 ANRIL 表达水平较低。其检测对疾病的诊断具有较好的灵敏度和特异性，其表达可能与患者预后不良有关。
